Business Context and Reporting Period
This Form 8-K, filed on November 30, 2023, reports on events occurring on November 26, 2023, regarding Chavant Capital Acquisition Corp. (Chavant) and its proposed business combination with Mobix Labs, Inc. (Mobix Labs). Upon closing, the combined entity will be named Mobix Labs, Inc. The filing details amendments to the Business Combination Agreement and new financing arrangements necessary to facilitate the transaction.
Key Financial Metrics and Obligations
The filing does not provide standard operating financial metrics such as revenue, profit, or cash flow for Mobix Labs or Chavant. However, it discloses specific financial obligations and transaction terms:
- Promissory Note: Chavant issued an unsecured note to its sponsor, Chavant Capital Partners LLC, for a principal amount of up to $325,000. The note bears interest at 10.0% per annum and is payable upon the earlier of the transaction closing or one year from issuance.
- PIPE Warrant: Mobix Labs issued a warrant to the PIPE Investor (ACE SO4 Holdings Limited) to purchase 700,000 shares of common stock at an exercise price of $0.01 per share. This warrant converts into 700,000 shares of Class A Common Stock upon closing.
- Net Tangible Assets Condition: The filing notes the removal of a condition requiring Chavant to have at least $5,000,001 of net tangible assets post-redemption and post-PIPE.
Material Changes Versus Prior Period
The filing outlines significant amendments to the original Business Combination Agreement dated November 15, 2022:
- Exchange Ratio Adjustment: The exchange ratio for converting Mobix Labs capital interests into Chavant Class A and Class B Common Stock has been adjusted to a one-to-one ratio.
- Deadline Extension: The deadline to complete the Proposed Transaction has been extended from November 22, 2023, to January 22, 2024.
- Condition Removal: The condition requiring a minimum of $5,000,001 in net tangible assets after redemptions and the PIPE investment has been deleted.
Guidance, Outlook, Risks, and Unusual Items
Outlook and Management Commentary: Management anticipates the transaction will close by the new deadline of January 22, 2024. The filing includes forward-looking statements regarding Mobix Labs' growth plans, technology advantages, and market positioning, though no specific financial guidance is provided in this document.
Risks and Contingencies: The filing highlights several material risks, including:
- Failure to complete the transaction by the extended deadline.
- Inability to satisfy conditions for consummation, including shareholder approval.
- Disruption to Mobix Labs' business operations and employee retention.
- Volatility in Chavant's securities price due to market conditions and the pending transaction.
- Risks related to the commercialization of Mobix Labs' semiconductor products and potential delays.
- Dependence on manufacturers, channel partners, and long sales cycles.
Unusual Items: The issuance of the PIPE Warrant at a nominal exercise price ($0.01) serves as consideration for the PIPE Investor's consent to the amendment of the Business Combination Agreement.
Important Facts for Investor Verification
- Verify the final terms of the Business Combination Agreement, specifically the one-to-one exchange ratio and the removal of the $5,000,001 net tangible asset condition.
- Confirm the status of the PIPE investment and the conversion of the 700,000 PIPE Warrants into common stock.
- Monitor the January 22, 2024, deadline for transaction completion and the potential for further extensions.
- Review the Supplemental Disclosures (Exhibit 99.1) referenced in the filing for updated information superseding the Proxy Statement/Prospectus.
- Assess the impact of the $325,000 promissory note on the combined company's post-transaction capital structure.